Dandruff & Seborrheic Scalp: ZPT vs Piroctone Olamine vs Ketoconazole Comparison

Overview #

Picking the wrong antifungal active is one of the fastest ways to kill a scalp product launch. Not because the ingredient doesn’t work — all three of these actives work — but because the wrong one in the wrong market, at the wrong concentration, in the wrong base will either fail regulatory review, fail stability, or fail the consumer’s sensory expectations. We’ve formulated all three across dozens of SKUs, and the selection logic is rarely as clean as supplier datasheets suggest.

The Three Actives: What They Actually Are on a Production Line #

Zinc Pyrithione (ZPT), Piroctone Olamine (PO), and Ketoconazole are not interchangeable. They share a mechanism — disrupting fungal cell membrane function, primarily targeting Malassezia species — but their formulation behavior is completely different.

ZPT is a suspension active. It doesn’t dissolve. Every batch we run with ZPT requires tight control of particle size distribution (typically 2–8 µm for scalp delivery) and viscosity to keep it uniformly suspended. If your shampoo base is too thin or your manufacturing shear is inconsistent, you get sedimentation. We’ve seen this on 200 kg batches where the first 20 kg dispensed from the tank had 40% higher ZPT concentration than the last 20 kg. That’s a compliance problem, not just a cosmetic one.

Piroctone Olamine is water-soluble at typical use concentrations (0.5–1.0%). It’s genuinely easier to work with. Cleaner aesthetics, no suspension headaches, and it plays well with most surfactant systems. The trade-off is cost — PO runs roughly 2.5–3× the raw material cost of ZPT at equivalent use levels. Most indie brands don’t price that in until we show them the COGS breakdown.

Ketoconazole is the outlier. It’s a pharmaceutical-grade antifungal, and in most markets it sits in a regulatory grey zone between cosmetic and drug. In the EU, it’s restricted under EU Cosmetics Regulation 1223/2009 — Annex III limits it to 2% in rinse-off products for dandruff control, with specific labeling requirements. In the US, the FDA Cosmetics Guidelines treat OTC ketoconazole shampoos as drug products, which means full OTC monograph compliance or NDA pathway. We almost always push back on ketoconazole briefs from brands that haven’t already mapped their regulatory pathway.

For deeper context on how we approach scalp-targeted delivery systems, see our encapsulation technology documentation — it’s relevant when you’re trying to extend residence time of any of these actives on the scalp.

The 4 Critical Selection Criteria #

1. Target Market and Regulatory Pathway — Decide This First

This is not a formulation question. It’s a business question that determines your formulation. If you’re launching in the EU and want to stay cosmetic (not drug), you’re choosing between ZPT and PO. Full stop. Ketoconazole at any meaningful concentration will trigger drug classification in most EU member states. In China, NMPA Cosmetic Regulation classifies dandruff shampoos as special-use cosmetics, which means a separate registration pathway regardless of which active you use — but ZPT and PO have cleaner precedent in the NMPA database.

2. Rinse-Off vs. Leave-On

ZPT is almost exclusively used in rinse-off formats. The suspension particle behavior, the zinc ion release kinetics, and frankly the consumer sensory profile all point to shampoo. We’ve tried ZPT in leave-on scalp serums. The texture is wrong and the stability is worse. PO is the better choice for leave-on formats — it’s soluble, it doesn’t leave a chalky residue, and at 0.5% in a leave-on tonic it remains stable across our standard 40°C/75% RH accelerated stability protocol for 12 weeks without significant degradation.

3. Efficacy Threshold and Clinical Positioning

If your brand needs clinical claims, the evidence base matters. The most relevant head-to-head data we reference internally comes from a double-blind, randomized controlled trial comparing 1% ZPT shampoo vs. 2% ketoconazole shampoo (n=246, 4 weeks, twice-weekly use). The ZPT arm showed 73% reduction in dandruff severity score; ketoconazole showed 88% reduction. Meaningful difference — but ketoconazole’s regulatory burden in most markets makes that 15-point gap hard to justify commercially. PO at 1% in a comparable study design (n=60, 8 weeks) showed 67% reduction in scalp flaking score. Honestly, for a cosmetic-positioned product, PO at 1% is where we’d start most briefs.

4. Formulation Compatibility and pH Window

ZPT is stable between pH 5.0–8.0. Below pH 5.0, zinc ion release accelerates and you get discoloration and potential irritation. PO is stable between pH 4.0–7.5, which gives you more flexibility for acidic scalp-balancing formulas. Ketoconazole requires pH 6.5–7.5 for optimal stability — which is actually inconvenient for modern scalp care, where the trend is toward lower-pH, microbiome-friendly formulations. Drop below pH 6.0 with ketoconazole and you start seeing crystallization in the base within 4–6 weeks at ambient temperature.

5. Surfactant System Compatibility

ZPT is sensitive to chelating agents. EDTA — which is in almost every shampoo base as a preservative booster — can complex with zinc and reduce efficacy. We use EDTA at ≤0.05% in ZPT formulas, or substitute with a non-chelating preservative system. PO is more forgiving. It’s compatible with anionic, amphoteric, and nonionic surfactant systems without significant interaction. We’ve run PO successfully in sulfate-free bases, which is increasingly what brand partners are requesting.

6. Sensory and Consumer Perception

This one is underrated. ZPT at 2% in a shampoo base has a slightly chalky, heavy feel on the scalp — some consumers interpret this as “medicated” and like it. Others don’t. PO at 1% is essentially invisible from a sensory standpoint. For premium positioning, PO wins. For mass-market “anti-dandruff” positioning where consumers expect a clinical feel, ZPT’s sensory profile can actually be an asset.

Where Most Brands Get This Wrong #

The brief usually says: “We want a dandruff shampoo with the strongest possible active.” That’s not a formulation brief. That’s a marketing wish.

Three out of five clients who come to us with a ketoconazole brief haven’t checked whether their target market allows it as a cosmetic. By the time we explain the OTC drug pathway in the US or the Annex III restrictions in the EU, the project scope has already shifted. We now require a confirmed regulatory pathway document before we start any ketoconazole development work. It saves everyone time.

The other common mistake is concentration. Brands assume more is better. At 2% ZPT, you’re at the regulatory maximum in the EU and you’re also at the edge of the stability window in many surfactant systems. We’ve had batches at 2% ZPT where the suspension became non-uniform by week 6 of PCT — not because the active degraded, but because the viscosity profile of the base shifted slightly with temperature cycling and the particles started to aggregate. Worked fine at 500 g lab scale. At 150 kg production, the shear history during transfer was different enough to change the particle size distribution. That batch had to be reworked.

Honestly, most brands underestimate how much the manufacturing process affects ZPT performance. It’s not just a formulation variable — it’s a process variable.

For brands exploring the microbiome angle alongside antifungal actives, our microbiome & probiotic skincare documentation covers how we approach combining postbiotic ingredients with antifungal systems without compromising either efficacy or stability.

The Cost Reality Nobody Talks About #

PO sounds like the obvious winner on paper — soluble, stable, good sensory, clean regulatory status. But at MOQ 1,000 units for a 200 mL shampoo, the raw material cost difference between 1% PO and 1% ZPT adds approximately $0.18–$0.25 per unit. That’s before packaging. For a brand pricing at $12 retail, that’s a meaningful COGS impact. For a brand pricing at $45, it’s irrelevant.

Ketoconazole is in a different cost tier entirely. At 2% in a 200 mL shampoo, the active alone adds roughly $0.60–$0.90 per unit at current supplier pricing. Add the regulatory compliance cost — testing, documentation, potentially OTC drug registration — and the total cost of goods for a ketoconazole product is typically 35–50% higher than an equivalent ZPT or PO formula. We’re still not convinced that cost is justified for most cosmetic-positioned brands unless they’re specifically targeting a clinical or dermatologist-recommended channel.

Formulation Notes for Brand Partners #

What market? What channel? What’s the on-pack claim you’re building toward?

Those are the first three questions we ask. A “dandruff shampoo” brief means something completely different for a mass-market EU launch versus a US dermatologist-channel product versus a China special-use cosmetic registration. The active selection, concentration, and base design all follow from those answers.

If you’re targeting EU cosmetic positioning with a clean-beauty angle, we’d typically propose PO at 0.5–1.0% in a sulfate-free, low-pH base (pH 5.0–5.5) with a postbiotic supporting ingredient. If you’re targeting a mass-market anti-dandruff claim with strong consumer recognition, ZPT at 1.0–1.5% in a conventional surfactant base is still the most cost-effective route. If you’re going clinical or Rx-adjacent, we need to talk about ketoconazole and your regulatory team needs to be in that conversation from day one.

For your brief, include these 7 items:

• Target market(s) and confirmed regulatory classification (cosmetic vs. OTC drug)
• Desired format (rinse-off shampoo, leave-on tonic, scalp treatment)
• On-pack claim language you’re planning to use
• Retail price point and target COGS range
• Fragrance and sensory preferences (clinical feel vs. premium aesthetic)
• Any ingredient restrictions (sulfate-free, silicone-free, vegan, etc.)
• Timeline and MOQ — this affects which actives are feasible at your scale

Frequently Asked Questions #

Q: Can we combine ZPT and Piroctone Olamine in the same formula for a stronger effect?

We’ve done this. At 0.5% ZPT + 0.5% PO in a rinse-off base, the combination is stable and within EU permitted levels for both actives. Whether the efficacy is meaningfully additive is honestly unclear — the clinical evidence for combination antifungal actives in cosmetic shampoos is thin. We’d only recommend it if your brand story specifically supports a “dual-action” positioning, because the cost increase isn’t trivial.

Q: We want to launch in both the EU and the US — which active works for both markets without triggering drug classification?

ZPT and PO are both cosmetic-permitted in the EU under Annex V. In the US, ZPT at ≤1% in a rinse-off shampoo falls under the OTC drug monograph for dandruff — which means you’re technically in drug territory even at cosmetic-level concentrations. PO has no established OTC monograph in the US, so it can be positioned as a cosmetic active. For a dual-market launch, PO at 0.5–1.0% is the cleaner path.

Q: How long does stability testing take for a ZPT shampoo before we can launch?

Our standard accelerated stability protocol runs 12 weeks at 40°C/75% RH, with additional cycling at -5°C to 45°C. For ZPT specifically, we also run a 6-month real-time study in parallel because the suspension behavior at ambient temperature doesn’t always predict from accelerated data alone. Realistically, plan for 6–8 months from formula lock to stability sign-off before launch.

Q: Can we use ketoconazole in a leave-on scalp serum?

Short answer: not in the EU as a cosmetic. Annex III restricts ketoconazole to rinse-off products only. In other markets the picture is more complicated, but a leave-on ketoconazole product will almost certainly be classified as a drug in any regulated market. We’d redirect that brief toward PO at 1% in a leave-on format — it’s the closest cosmetic-compliant equivalent.

Q: What’s the minimum order quantity to run a ZPT shampoo on your line?

Our standard MOQ for a ZPT suspension shampoo is 500 kg per batch, which typically yields approximately 2,500 units at 200 mL fill weight. Below that threshold, the suspension homogeneity QC becomes harder to guarantee because the mixing dynamics change at smaller batch sizes. We’ve run 200 kg pilot batches for development purposes, but we don’t recommend commercial launch at that scale.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.